logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 8987271 B1

PDFFull Text
Date of Patent:
Mar. 24, 2015

Filed:

Dec. 22, 2011

2,2'-biphenazine compounds and methods useful for treating disease

Applicants:

Michael H. Cardone, Dorchester, MA (US);

Xiang Y. Yu, Acton, MA (US);

Andrew F. Kolodziej, Winchester, MA (US);

Inventors:

Michael H. Cardone, Dorchester, MA (US);

Xiang Y. Yu, Acton, MA (US);

Andrew F. Kolodziej, Winchester, MA (US);

Assignee:

Eutropics Pharmaceuticals, Inc., Cambridge, MA (US);

Attorney:

Cooley LLP

Primary Examiner:

Douglas M Willis

Int. Cl.
CPC ...
A61K 31/498 (2006.01); C07D 241/46 (2006.01); C07C 217/92 (2006.01); C07C 229/18 (2006.01); C07C 229/34 (2006.01); C07C 229/36 (2006.01); C07C 229/48 (2006.01); C07C 229/58 (2006.01); C07C 229/60 (2006.01); C07C 229/64 (2006.01); C07C 311/21 (2006.01); C07C 317/36 (2006.01); C07C 317/44 (2006.01); C07D 209/08 (2006.01); C07D 209/34 (2006.01); C07D 211/46 (2006.01); C07D 211/60 (2006.01); C07D 213/79 (2006.01); C07D 215/48 (2006.01); C07D 231/14 (2006.01); C07D 231/38 (2006.01); C07D 235/26 (2006.01); C07D 239/28 (2006.01); C07D 239/42 (2006.01); C07D 261/18 (2006.01); C07D 263/34 (2006.01); C07D 263/48 (2006.01); C07D 309/14 (2006.01);
U.S. Cl.
CPC ...
C07D 241/46 (2013.01); C07C 217/92 (2013.01); C07C 229/18 (2013.01); C07C 229/34 (2013.01); C07C 229/36 (2013.01); C07C 229/48 (2013.01); C07C 229/58 (2013.01); C07C 229/60 (2013.01); C07C 229/64 (2013.01); C07C 311/21 (2013.01); C07C 317/36 (2013.01); C07C 317/44 (2013.01); C07D 209/08 (2013.01); C07D 209/34 (2013.01); C07D 211/46 (2013.01); C07D 211/60 (2013.01); C07D 213/79 (2013.01); C07D 215/48 (2013.01); C07D 231/14 (2013.01); C07D 231/38 (2013.01); C07D 235/26 (2013.01); C07D 239/28 (2013.01); C07D 239/42 (2013.01); C07D 261/18 (2013.01); C07D 263/34 (2013.01); C07D 263/48 (2013.01); C07D 309/14 (2013.01); C07C 2101/08 (2013.01); C07C 2101/14 (2013.01);
Abstract

The invention relates to a chemotherapeutic cancer treatment in which compounds (BH3Is) are administered to a mammal to treat B-cell Lymphoma or other hematopoietic cancers, including diseases associated with MCL-1. The invention also provides a method for treating types of hematopoietic cancers, such as B-cell lymphoma, using a combination of one or more disclosed compounds in combination with other therapies, for example, 26S proteosome inhibitors, such as, for example, Bortezomib. The invention also relates to autoimmune treatment with pharmaceutical compositions comprising one or more disclosed compounds. The invention also relates to methods for identifying compounds, for example, compounds of the BH3 mimic class, that have unique in vitro properties that predict in vivo efficacy against B-cell lymphoma tumors and other cancers as well as autoimmune disease. Illustrative compounds are those of Formula II:

Find Patent Forward Citations

Loading…